Health Canada approves ELAHERE for certain types of platinum resistant ovarian cancers

CAR-T Digest - August 2020

02 September 2025: Health Canada approves ELAHERE for certain types of platinum resistant ovarian cancers

Health Canada has approved ELAHERE (mirvetuximab soravtansine), an antibody-drug conjugate, for adult patients with folate receptor-alpha positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer after one to three prior therapies
The approval, granted under the Priority Review process, was based on pivotal MIRASOL Phase 3 trial data showing significant overall survival benefits compared to chemotherapy
ELAHERE is the first and only ADC in Canada targeting FRα, offering a new standard of care for a disease with the lowest survival rate among gynecological cancers
Patient advocacy groups and clinical experts welcomed the approval, highlighting the urgent need for effective treatments in platinum-resistant ovarian cancer, which has limited therapeutic options and poor prognosis
AbbVie emphasized this as the first new treatment in over a decade for this cancer type, reinforcing its commitment to advancing therapies for difficult-to-treat cancers